Etoposide

製品コードS1225 別名:VP-16, VP-16213

Etoposide化学構造

分子量(MW):588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 46480.00

カスタマーフィードバック(6)

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
ターゲット
Topo II [2]
(Cell-free assay)
体外試験

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnTR25nUUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> M4n2XlI2QTZyMkiy
KellyCis83 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTKV3dKSzVyPUCuNVbjiIoEsfMAjVAvODJizszN NIS1SpQzPTl4MEK4Ni=>
SK-N-AS M{Xpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jOTWlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= M3\YWlI2QTZyMkiy
SK-N-ASCis24 M3HHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fXPGlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= NWDwUoZlOjV7NkCyPFI>
U87 M2PRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILzN5ExNTVyIN88US=> MX[0PEBp M{DaToRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nlic3nsbYJqdmmw NXr5T4R[OjV5NUCyO|M>
HCT116 M176SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWewMlUuOi53IN88US=> M2HBbVQ5yqCqwrC= MWrJR|UxRTFwN{RCpOKyyqByLkKxxsDPxE1? M2fpOFI2PzR4N{[z
HT-29 NHi5ZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHOXlczOC53LUKuOUDPxE1? Mmj1OFjDqGkEoB?= M4PG[GlEPTB;Nz6yxsDDucLiMT6wOOKh|ryP MmPVNlU4PDZ5NkO=
Caco2 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHscYwxNjVvMj61JO69VQ>? MlrYOFjDqGkEoB?= MVrJR|UxRTdwMkdCpOKyyqBzLk[4xsDPxE1? MlLsNlU4PDZ5NkO=
COLO 205 NI[yRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS2bncxNjVvMj61JO69VQ>? MofLOFjDqGkEoB?= MmTvTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP NGj1RnAzPTd2Nke2Ny=>
SW480 NHj3N3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHUTXAxNjVvMj61JO69VQ>? MVi0POKhcMLi M1;jNWlEPTB;ND65NuKhyrIEoECuN|PDqM7:TR?= MUeyOVc1Pjd4Mx?=
HEK293T NIjuWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LTcVEuPSEQvF2= MXm0POKhcMLi NH3RNYZKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= MlvtNlU4PDZ5NkO=
Hep3B  NYfGeoQ3TnWwY4Tpc44hSXO|YYm= MonTNVAh|ryP NHG4RYM1QMLiaNMg M2HPW5Jm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> NVm2V|BkOjV4M{O1OlQ>
Hep3B  M1HlUGZ2dmO2aX;uJGF{e2G7 MWqwMlEuOTBizszN NWLNbHdZOjRiaB?= Ml\4d5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBp\XClaXTpckBuWk6D NVXEcGFyOjV4M{O1OlQ>
HEK293 MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vU[2lEPTB;Nz6xOOKhyrIEoECuN|bDqM7:TR?= NGnnXVczPTZyM{GyNi=>
DU145 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fSVGlEPTB;Mj6yPOKhyrIEoECuNFTDqM7:TR?= M136RlI2PjB|MUKy
HCT15 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XXVGlEPTB;MD64NeKhyrIEoECuNFHDqM7:TR?= M1rxPFI2PjB|MUKy
T47D NWHtSnE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz0TWM2OD1|LkG4xsDDucLiMD6xNeKh|ryP M4CySVI2PjB|MUKy
SMMC-7721 M1vDNmZ2dmO2aX;uJGF{e2G7 MXW0NEDPxE1? NGe2dpk1QCCq MoLJSG1UVw>? MVPpcoR2[2W|IN8zTFJCYCCob3PpJIZwem2jdHnvci=> NETn[3IzPTV2NEO2NS=>
MDA-MB-231 M121S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTheJplPzMEoHi= MnvDTWM2OD1{MT6yxsDDucLiND6yxsDPxE1? NGHpfFYzPTR6NkKxPS=>
MCF-7 M1vOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3hO|LDqGh? M{H4UWlEPTB;MUCuPeKhyrIEoEKuNeKh|ryP M{DFd|I2PDh4MkG5
Jurkat NF;CW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK3NuKhcA>? MUTJR|UxRTFwMtMgxtHDqDFwNdMg{txO NXTTO4tHOjV2OE[yNVk>
HeLa NVvNT5U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLQZ2JrPzMEoHi= NYDqSIh[UUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= MYOyOVQ5PjJzOR?=
MCF7  NIfDe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO1MVExOCEQvF2= NF3wdXI4KGR? MmHGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXyyOVQ4OjZzOR?=
K562 M2LlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWzdot2PzMEoHi= M4rjWmlEPTB;MD6yPeKh|ryP NW\JPXlNOjV{OEK2OVM>
K/VP.5 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LGeFczyqCq NECye4RKSzVyPUSuPeKh|ryP M{iwU|I2Ojh{NkWz
SH-EP  M3npWGZ2dmO2aX;uJGF{e2G7 MYWyNOKh|rypL33s NXTCfFE5OjUEoHi= NY\WN4k2cW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> NVf5RXlbOjV{NkG5PFE>
SCC25 M4naWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqyOOKhcA>? MUDJR|UxRTR|LkRCpOKyyqBzLkGyxsDPxE1? NEfw[WkzPTJ{MEeyPS=>
CAL27 M4PZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu2NlTDqGh? MlnqTWM2OD13Mj6xxsDDucLiMT6wPeKh|ryP MVOyOVIzODd{OR?=
FaDu NHq5[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXeyOOKhcA>? NF73OnNKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN M1;xeVI2OjJyN{K5
SCC25 NVvoeXo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO0POKhcA>? MUnJR|UxRTJyLki2xsDDucLiMT6wO:Kh|ryP Ml3oNlUzOjB5Mkm=
CAL27 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvyNHU1QMLiaB?= NHfycnZKSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN MljSNlUzOjB5Mkm=
FaDu MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy1fYRIPDkEoHi= MX\JR|UxRTZwNERCpOKyyqBzLkGzxsDPxE1? NYKzZ3JxOjV{MkC3Nlk>
SCC25 NVHDWo1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NESwTYk4OsLiaB?= NXu5c3N7UUN3ME24MlQyyqEEsdMgNU4yOcLizszN Mn2wNlUzOjB5Mkm=
CAL27 NWnZN2Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK0cXE4OsLiaB?= NWK0SWpSUUN3ME20MlI4yqEEsdMgNU4yPMLizszN MmjGNlUzOjB5Mkm=
FaDu MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTkXlB3PzMEoHi= NF3ZXolKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= NHG4O|UzPTJ{MEeyPS=>
MCF-7 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX0NHk1QMLiaNMg Mom1SG1UVw>? M1L4SWlEPTB;Nz6yxsDDucLiMD64xsDPxE1? M{fIW|I2OjF4M{e4
T-47D MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK0POKhcMLi NXnZeZh{TE2VTx?= M4C4emlEPTB;Nz63xsDDucLiMD63xsDPxE1? MWOyOVIyPjN5OB?=
MDA-MB-231 NHHCc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7IWYk1QMLiaNMg M2XYZmROW09? NVrVbZVqUUN3ME2xNk45yqEEsdMgNU4xyqEQvF2= NXfTPFNZOjV{MU[zO|g>
DU145 NXHFT4FOSXCxcITvd4l{KEG|c3H5 NYXsZY5DOTBvMUCwJO69VQ>? MWK4JIg> MoriSG1UVw>? MlnZbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w NIDjSngzPTF2OU[4NS=>
DU145 stem-like MmHpRZBweHSxc3nzJGF{e2G7 MY[xNE0yODBizszN NWLsUmhkQCCq MUjEUXNQ NVHJN|BycW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXeyOVE1QTZ6MR?=
DU145 Mk[5SpVv[3Srb36gRZN{[Xl? NVi5fFNROTBvMUCwJO69VQ>? MUSyJIg> NVnPO5NXTE2VTx?= MW\pcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHi0bYIzPTF2OU[4NS=>
DU145 stem-like MWrGeY5kfGmxbjDBd5NigQ>? NHnI[HkyOC1zMECg{txO NHTDUI0zKGh? MXPEUXNQ NEfl[4xqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUPCXGM{OjVzNEm2PFE>
UW228-3 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P0TVAvODFvM{CwJO69VQ>? Mn;TOFghcA>? NULrV3RWTE2VTx?= MV7JR|UxRTBwOUpCpO69VQ>? MWWyOVEyQTF6NR?=
NSCs NW\4SFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qyRVAvODFvM{CwJO69VQ>? MlXKOFghcA>? M{PiPWROW09? M2rzSWlEPTB;MD6zMVPDqM7:TR?= MmD4NlUyOTlzOEW=
MKL-1  M3GyWGZ2dmO2aX;uJGF{e2G7 NY\mU|BzOTBvMUCwNEBvVQ>? NYm0Z2d5PCCm MYHpcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? NVjD[3p1OjVzMU[3OVQ>
MCF7 EV MoLZSpVv[3Srb36gRZN{[Xl? NF7J[WIyOC1zMECg{txO MkjlNwKBkWh? M3f1Volv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ MYGyOVA5QDJyMx?=
MCF 7BMI1 Mo\oSpVv[3Srb36gRZN{[Xl? MXGxNE0yODBizszN NFq1NpUz6oDLaB?= MWDpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> M12wR|I2ODh6MkCz
MCF7 EV MojjSpVv[3Srb36gRZN{[Xl? MkLTNVAuOTByIN88US=> NUTu[5ZjOuLCiXi= MYXFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= NY\neZdqOjVyOEiyNFM>
MCF7 BMI1 Mn34SpVv[3Srb36gRZN{[Xl? MYexNE0yODBizszN NUe5N2tQOuLCiXi= MlzQSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u MoLwNlUxQDh{MEO=
HepG2 NVflcppqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7EUXNQyqB? NHfiXHNKSzVyPUOwMlE3yqEEsdMgNE42OMLizszN NWTIRlg5OjVyN{izNVE>
MOLT-3 NVvYU5B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS1OI44TE2VT9Mg M1zVNWlEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN MonRNlUxPzh|MUG=
HT1080 M3jaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWxMVExOCEQvF2= NWK4[5hxPC9{ND:0PEBp MVjEUXNQyqB? MnvBbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w M1\ENlI2ODd6ME[0
HT1080 NFjpc4pHfW6ldHnvckBCe3OjeR?= MkfnNE4xODBzLUGwNEDPxE1? NX7V[YV1OS1{NDDo MW\EUXNQyqB? NWLqfZlEcW6mdXPld{BxNXB3Mzjz[ZIyPSliaX6gZo91cCC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy NGfGfWIzPTB5OEC2OC=>
HT1080 NWDVVWRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGwMlAxODFvMUCwJO69VQ>? NV76blA1OjRiaB?= NXTHPGRPTE2VT9Mg MlzQZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= MVeyOVA4QDB4NB?=
HD-MY-Z MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;vNXhsOjRxNEivO|IhcA>? MonGTWM2OO,:nkGwNEDPxE1? NEDkbGYzPTB2OEKzOi=>
DOHH-2 NYfxUXNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\ocVI1KGh? NHi2cZFKSzVy78{eNVAxKM7:TR?= MV6yOVA1QDJ|Nh?=
DOHH-2 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXS0PEBp NV;iUXF6UUN3ME2xPU46yqEQvF2= MkC2NlUxPDh{M{[=
DOHH-2 NXvTOXFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD1eHBmPzJiaB?= M3nCbmlEPTB;NdMg{txO MkfNNlUxPDh{M{[=
REH NHO3UpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWzR3pkOjRiaB?= NIfqWG1KSzVyPUCuNFI4yqEQvF2= MVKyOVA1QDJ|Nh?=
REH MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X6TVQ5KGh? MkS1TWM2OD1yLkCxOOKh|ryP MmXwNlUxPDh{M{[=
REH NU\VOGxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz6THBmPzJiaB?= MWPJR|UxRTBwMEG1xsDPxE1? MonGNlUxPDh{M{[=
HH M3rZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\zNlQhcA>? MWnJR|UxRTFyND63xsDPxE1? M3ToZVI2ODR6MkO2
HH M1Ph[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fXclQ5KGh? Mn\KTWM2OD12OD62xsDPxE1? NW\BRlA3OjVyNEiyN|Y>
HH M1Xpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTEVYRTPzJiaB?= M2C0R2lEPTB;MUSuO:Kh|ryP NYrKWXplOjVyNEiyN|Y>
HuT-78 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITNNlczPCCq NHjOcFJKSzVyPUmuN:Kh|ryP NUX3PFR4OjVyNEiyN|Y>
HuT-78 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjIWmM5PDhiaB?= M2nISGlEPTB;ND6zxsDPxE1? NXHPUpBnOjVyNEiyN|Y>
HuT-78 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS3NkBp NX73TI46UUN3ME20MlLDqM7:TR?= MWeyOVA1QDJ|Nh?=
OPM-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;wNlQhcA>? M3;semlEPTB;MkSuNeKh|ryP NIf4XHgzPTB2OEKzOi=>
OPM-2 NIPobGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG3OFghcA>? NIfTXlJKSzVyPUVCpO69VQ>? Mk\vNlUxPDh{M{[=
OPM-2 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LmTVczKGh? MVnJR|UxRTFwM9Mg{txO NGPnemMzPTB2OEKzOi=>
RPMI-8226 M1;yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV2yOEBp NIXhc4FKSzVyPUGwOk43yqEQvF2= NYCx[IZiOjVyNEiyN|Y>
RPMI-8226 NWrrdZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XD[FQ5KGh? M{jwS2lEPTB;OUGuNeKh|ryP M1fMcVI2ODR6MkO2
RPMI-8226 M{flRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPlO|IhcA>? MYrJR|UxRTF2LkpCpO69VQ>? MXeyOVA1QDJ|Nh?=
U-266 NYTB[|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGyfYkzPCCq MWfJR|UxRTh4LkNCpO69VQ>? MlvjNlUxPDh{M{[=
U-266 NEm0TGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnxWpFVPDhiaB?= NFnvWIhKSzVyPU[4MlTDqM7:TR?= NYLoRo45OjVyNEiyN|Y>
U-266 M2fvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITuT4I4OiCq NEDlTXBKSzVyPUK3MlTDqM7:TR?= Ml65NlUxPDh{M{[=
Kelly NGjlUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzMNnYxNTFyIN88US=> NHPDOXM4OsLiaB?= NWTTU3hKUUN3ME2xMlUyQMLizszN M4r3eFI2ODB6OUCw
SH-SY5Y  NW\CbGRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK2NlAxNTFyIN88US=> M3rSflczyqCq MY\JR|UxRTBwN{W0xsDPxE4EoB?= NVXLS2x3OjVyMEi5NFA>
SK-N-AS MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLiTXcxNTFyIN88US=> NIPr[Yg4OsLiaB?= MmXDTWM2OD1zLkexNuKh|ryPwrC= NHHQd4UzPTByOEmwNC=>
SK-N-DZ MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrBSGQ2OC1zMDFOwG0> M2nqbVczyqCq M{PTemlEPTB;NT60PFXDqM7:TR?= M4iydlI2ODB6OUCw
HepG2 M{LpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYi0POKhcA>? MV7EUXNQyqB? M4fje2lEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= MVuyOFk6PjF|Nh?=
A549 M3HqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK0POKhcA>? MlXYSG1UV8Li MWLJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NEfNSlgzPDl7NkGzOi=>
MCF7 NGnwe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWm0POKhcA>? MX\EUXNQyqB? MoHWTWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= NFrINZkzPDl7NkGzOi=>
HL-60  NXr4RXVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zt[|czyqCq MWTJR|UxRTBwMUNihKXPxE1? NGTwUWczPDl7M{CxOC=>
HL-60[R] M2m5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmzUVc4OsLiaB?= NIfxNXhKSzVyPUOuNVLjiIYQvF2= NE[zWoYzPDl7M{CxOC=>
MIAPACA MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\uUXlRT0l3ME2xMlMhyrFiMD6wN{DPxE1? MkXONlQ6PTN6MkG=
MCF-7 M2TJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvyOVVIUTVyPUCuNlUhyrFiMD6xJO69VQ>? MoLWNlQ6PTN6MkG=
HeLa NWPKcXVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyzSI1kT0l3ME2wMlY1KMLzIECuOEDPxE1? M1vZPVI1QTV|OEKx
MO59K  MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm3JIQ> M4DwWmlEPTB;MD6xO-KBjc7:TR?= M4HMd|I1QTV|NU[x
MO59J NIDqU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPnNIQ4KGR? MX;JR|UxRTBwMfMAie69VQ>? Mmn0NlQ6PTN3NkG=
ME 180 NIPl[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m3[VQ5yqCqwrC= MojETWM2OD16LkpCpOKyyqByLkRihKXPxE1? NUCyb|JxOjR7NUOwNlc>
MCF-7 NX3PVZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj1UGZ6PDkEoHlCpC=> MVfJR|UxRTJ|LkmgxtEhOC5|4pEF{txO MW[yOFk2OzB{Nx?=
HeLa NVK4[VVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVy0POKhcMLi NWDsTJMzUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= NGDyV2MzPDl3M{CyOy=>
MDA-MB-453 M{PxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICy[XY1QMLiaNMg Mn6xTWM2OD1zMj61JOKyKDBwOEZihKXPxE1? MVOyOFk2OzB{Nx?=
MDA-MB-231 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHs[Wx2PDkEoHlCpC=> MXzJR|UxRTJ2LkKyJOKyKDJwOUVihKXPxE1? M4jtN|I1QTV|MEK3
PC-3 M4nWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vKR|Q5yqCqwrC= NXn4SWtxUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= M3jHN|I1QTV|MEK3
HT-29 Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLFO4p7PDkEoHlCpC=> Mk[yTWM2OD1{MT60OUDDuSB|Lki35qCG|ryP NHPCeVMzPDl3M{CyOy=>
BGC-823 M2\HSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zxSVQ5yqCqwrC= MmKzTWM2OD12Mz63OEDDuSB3LkGz5qCG|ryP MWOyOFc6Ozh5Nx?=
HeLa Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUe0POKhcMLi MYLJR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= NFTa[YYzPDd7M{i3Oy=>
A549 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm0POKhcMLi NHHRbXlKSzVyPUGzPU42PCEEsTC3MlA26oDHzszN NIfnTHUzPDd7M{i3Oy=>
HK-2 NYLVVXI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fQb|Q5yqCqwrC= M{LDVGlEPTB;OT6xO{DDuSBzLkW45qCG|ryP NWjzSG13OjR5OUO4O|c>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
+ 展開

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
細胞試験: [5]
+ 展開
  • 細胞株: Human glioma cell lines CL5
  • 濃度: 80 μg/mL
  • 反応時間: 1 hour
  • 実験の流れ: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Murine angiosarcoma xenografts ISOS-1
  • 製剤: Saline
  • 投薬量: 10 mg/kg
  • 投与方法: i.p. every day for 5 days from day 7
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
5% DMSO+30% PEG 300+H2O
混合させたのち直ちに使用することを推奨します。
15mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 588.56
化学式

C29H32O13

CAS No. 33419-42-0
保管
in solvent
別名 VP-16, VP-16213

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomeraseシグナル伝達経路

相関Topoisomerase製品

Tags: Etoposideを買う | Etoposide ic50 | Etoposide供給者 | Etoposideを購入する | Etoposide費用 | Etoposide生産者 | オーダーEtoposide | Etoposide化学構造 | Etoposide分子量 | Etoposide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID